medigraphic.com
ISSN 1560-4381 (Print)

2012, Number 2

<< Back Next >>

Correo Científico Médico 2012; 16 (2)

Risk Factors and Prevention of Ischemic Heart Disease

Tarragó AE, Soca PEM, Cruz LLA, Santiesteban LY

Language: Spanish
References: 32
Page:
PDF size: 123.99 Kb.


ABSTRACT

The ischemic heart disease is the most important cause of death in the world and it is manifested in different ways. The most serious manifestation in this affection is the heart attack, angina pectoris, and the sudden cardiac death. It is associated with risk factors including sedentarism, inadequate diets, the increase of the adiposity, smoking habits, the intolerance to the glucose or type 2 diabetes mellitus and the hypertension not controlled. Its prevention requires a great dose of will and changes in the lifestyles.


REFERENCES

  1. 1 Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al (eds.). Las prioridades de la salud. Washington: Banco Mundial; 2006.

  2. 1 Chauhan U. Cardiovascular disease prevention in primary care. Br Med Bull. 2007; 81-82 65-79.

  3. 2 Oficina Nacional de Estadísticas de Cuba. Anuario Estadístico de Cuba 2007. Cuba [citado 9 nov 2009]. Disponible desde: http://www.one.cu/aec2007/esp/20080618_tabla_cuadro.htm

  4. 3 Organización Mundial de la Salud. Evite los infartos de miocardio y los accidentes cerebrovasculares. No sea víctima, protéjase. Ginebra: Organización Mundial de la Salud; 2005.

  5. 4 Cáceres Lóriga FM, Ramírez Hernández RA. Protocolo de tratamiento de la cardiopatía isquémica en la atención primaria de salud. Rev Cub Farm. 2002; 36(1):69-72.

  6. 5 Medina Lezama J, Morey Vargas OL, Zea Díaz H, Bolaños-Salazar JF, Corrales Medina F, Cuba Bustinza C, et al. Prevalence of lifestyle-related cardiovascular risk factors in Peru: the PREVENTION study. Rev Panam Sal Pub. 2008; 24(3):169-79.

  7. 6 Noval García R De la, Armas Rojas NB, Noval González I de la, Fernández González Y, Pupo Rodríguez HB, Dueñas Herrera A, et al. Estimación del Riesgo Cardiovascular Global en una población del Área de Salud Mártires del Corynthia. La Habana. Rev Cub Cardiol Cir Cardiovasc. 2011 [citado 24 nov 2011]; 17(1):62-68. [Aprox 9p.]. Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/issue/view/2.

  8. 7 Miguel Soca PE. El síndrome metabólico: un alto riesgo para individuos sedentarios. Acimed. 2009 Sep [citado 4 nov 2010]; 20(2): [Aprox 3p.]. Disponible en : http://bvs.sld.cu/revistas/aci/vol20_2_09/aci07809.pdf

  9. 8 Ignarro LJ, Balestrieri ML, Napoli C. Nutrition, physical activity, and cardiovascular disease: An update. Cardiovasc Res. 2007; 73: 326-40.

  10. 9 Miguel Soca PE, Niño Peña A. Consecuencias de la obesidad. Acimed. . [Internet] 2010 Sep [citado 3 nov 2010].20 (4). Disponible en: http://bvs.sld.cu/revistas/aci/vol20_4_09/aci061009.pdf

  11. 10 Millán J. Tratamiento de la dislipemia en pacientes con síndrome metabólico o con diabetes mellitus. Med Clin (Barc). 2007; 128 (20):786-94.

  12. 11 Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007; 74: 11-18.

  13. 12 Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis. 2009; 205 (1):23-32.

  14. Correo Científico Médico ISSN 1560-4381 CCM 2012; 16 (2)

  15. 13 Paraskevas KI, Stathopoulos V, Mikhailidis DP, Perrea D. Smoking, abdominal aortic aneurysms, and ischemic heart disease: Is there a link? Angiology. 2009; 59(6):664-6.

  16. 14 Lugones Botell M, Ramírez Bermúdez M, Pichs García LA, Miyar Pieiga E. Las consecuencias del tabaquismo. Rev Cub Hig Epidemiol. 2009 Sep 2006; [citado 9 nov 2010].44 (3). Disponible en: http://www.bvs.sld.cu/revistas/hie/vol44_3_06/hie07306.htm

  17. 15 Miguel Soca PE. Dislipidemias. Acimed. 2009 [citado 9 nov 2011]; 20(6). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1024- 94352009001200012&lng=es&nrm=iso&tlng=es.

  18. 16 Freitas EV, Brandão AA, Pozzan R, Magalhães ME, Fonseca F, Pizzi O, et al. Importance of HDL-c for the Occurrence of Cardiovascular Disease in the Elderly. Arq Bras Cardiol. 2009; 93(3): 216-22.

  19. 17 Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004; 164(13):1422-6.

  20. 18 Gerich JE. Hypoglycaemia and counterregulation in type 2 diabetes. Lancet. 2000;356(9246):1946-7.

  21. 19 Davis N, Forbes B, Wylie-Rosett J. Nutritional strategies in Type 2 Diabetes. Mt Sinai J Med. 2009; 76:257-68.

  22. 20 Miguel Soca PE, Sarmiento Teruel Y. Hipertensión arterial, un enemigo peligroso. Acimed. 2009 Sep [citado 4 ene 2011]; 20(3). Disponible en: http://bvs.sld.cu/revistas/aci/vol20_3_09/aci07909.pdf

  23. 21 Schindler C. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Ther Adv Cardiovasc Dis. 2007; 1(1) 7-26.

  24. 22 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640-5.

  25. Correo Científico Médico ISSN 1560-4381 CCM 2012; 16 (2)

  26. 23 Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, et al. Prevalence of the Metabolic Syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovasc Diabetol. 2009 [citado 22 nov 2011]; 8:52. Disponible en: http://www.cardiab.com/content/8/1/52.

  27. 24 Böhm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007; 76:8-18.

  28. 25 Kinnaird T, Stabile E, Zbinden S, Burnett MS, Epstein SE. Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions. Cardiovasc Res. 2008; 78: 257-64.

  29. 26 Von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res. 2007; 73:310-5.

  30. 27 Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, et al. On behalf of EUROACTION Study Group Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet. 2008; 371:1999-2012.

  31. 28 Kastelein JP, Akdim F, Stroes E, Zwinderman AH, Bots M, Stalenhoef A, et al., for the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358:1431-43.

  32. 29 Gomes MB, Giannella-Neto D, Faria M, Tambascia M, Fonseca RM, Rea R, et al. Estimating cardiovascular risk in patients with type 2 diabetes: a national multicenter study in Brazil. Diabetol Metab Syndr. 2009 Sep. [citado 21 ene 2011]. 1:22. Disponible en: http://www.dmsjournal.com/content/1/1/22.




2020     |     www.medigraphic.com